We are an established manufacturer and supplier of railway and metro equipments, and allied components for the locomotive and coach applications segment in India, with a strong presence across both diesel-electric and electric platforms (Source: 1Lattice Report). We commenced operations in 2001 with the manufacture and supply of filters for railway and automotive applications and have since diversified into the manufacture and supply of traction motors, alternators, brake discs, gangways, stators and rotors for locomotives, platform screen doors for metros, wind generators and allied services. In line with our strategy to diversify our product portfolio, we expanded into the renewable energy sector in 2023 through the manufacture and supply of wind generators, and also executed orders from leading wind turbine manufacturers for the supply of wind generators indicating initial market acceptance of our offerings in the renewable energy domain (Source: 1Lattice Report). Pursuant to this expansion, we have established in-house production capabilities for wind generators, positioning us among the limited number of players in India with manufacturing capabilities in this segment (Source: 1Lattice Report). Our entry into this sector leverages our existing technical expertise, fabrication infrastructure and quality systems, enabling us to cater to the requirements of renewable energy developers and related stakeholders. We have executed orders from one of the leading wind turbine manufacturers for the supply of 129 sets of wind generators during the fiscal 2026, of which 117 sets were supplied between October 1, 2025, and February 28, 2026, evidencing initial market acceptance of our offerings in the renewable energy domain.
| Investory Category | Subscription Percentage | Amount Raised (₹ Crores) |
|---|---|---|
| Qualified Institutional Buyers (QIBs) | 0% | -- |
| Non-Institutional Investors (NIIs) | 0% | -- |
| Retail Individual Investors (RIIs) | 100% | -- |
Pioneer Fil Med’s total income 0.00 by 0.00% and total expenses 6,649.35 by -20.08%, resulting in an EBITDA 4,032.4 by 113.47% and a profit after tax (PAT) 0.00 by 0.00% between March 31, 2025 and March 31, 2026.
6,649.3531 March 2026 | 8,319.531 March 2025 | 7,216.2231 March 2024 |
4,032.431 March 2026 | 1,888.9931 March 2025 | 1,005.9931 March 2024 |
8,319.5
7,488
6,656
5,824
4,992
4,160
3,328
2,496
1,664
832
0.00
| Allotment Date | Listing Date | Refund Date |
|---|---|---|
| -- | -- | -- |
| Issue Composition: | |
|---|---|
| Face Value | ₹10 per share |
| Total Issue Size | 0 shares (aggregating up to To be announced) |
| Fresh Issue | 0 shares (aggregating up to To be announced) |
| Offer for Sale | 0 shares of ₹10 (aggregating up to To be announced) |
| Issue Type | Book building |
| Post-Issue Shareholding Pattern: | |
|---|---|
| Pre-Issue Shareholding | 95 shares |
| Post-Issue Shareholding | 0 shares |
| Minimum Lot Size | -- |
| Maximum Lot Size (Retail) | -- |
The lot size of Pioneer Fil Med ipo has been designed to ensure broad participation while maintaining optimal price discovery.
502 Padma Palace 86 Nehru Place New Delhi
| Book Running Lead Manager(s) |
|---|
| Nuvama Wealth Management Ltd | Equirus Capital Pvt Ltd |